PE15602016A1 - PCSK9 vaccine - Google Patents

PCSK9 vaccine


Publication number
PE15602016A1 PE2016002242A PE0022422016A PE15602016A1 PE 15602016 A1 PE15602016 A1 PE 15602016A1 PE 2016002242 A PE2016002242 A PE 2016002242A PE 0022422016 A PE0022422016 A PE 0022422016A PE 15602016 A1 PE15602016 A1 PE 15602016A1
Prior art keywords
seq id
amino acid
acid sequence
immunogenic composition
Prior art date
Application number
Other languages
Spanish (es)
David Michael Wyatt
Jakir Hussain Ullah
Xiayang Qiu
Brian Gregory Pierce
Brian Robert Champion
Julie Jia Li Hawkins
James Downey Fraser
Michael Dale Eisenbraun
Jr Leonard Gabriel Contillo
James Richard Merson
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US23954109P priority Critical
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of PE15602016A1 publication Critical patent/PE15602016A1/en



    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21061Kexin (, i.e. proprotein convertase subtilisin/kexin type 9


Se refiere a una composicion inmunogenica que comprende al menos dos peptidos antigenicos de PCSK9 donde: a) el primer peptido antigenico de PCSK9 consiste en una secuencia de aminoacidos de SEQ ID NO: 182 a 226, 317 y 401 a 403; It relates to an immunogenic composition comprising at least two antigenic peptides the PCSK9 where: a) the first PCSK9 antigenic peptide is an amino acid sequence of SEQ ID NO: 182-226, 317 and 401-403; yb) el segundo peptido antigenico de PCSK9 consiste en una secuencia de aminoacidos de SEQ ID NO: 46-101, 314, 318 y 319; b) the second PCSK9 antigenic peptide consists of an amino acid sequence of SEQ ID NO: 46-101, 314, 318 and 319; c) un vehiculo inmunogenico tal como CRM197 o VLP de Qbeta; c) an immunogenic carrier such as CRM197 or VLP Qbeta; d) un adyuvante tal como alumbre, CpG ODN, QS21 e Iscomatrix. d) an adjuvant such as alum, CpG ODN, QS21 and Iscomatrix. Dicha composicion inmunogenica es util en el tratamiento, alivio o profilaxis de enfermedades asociadas con un nivel elevado de colesterol. Said immunogenic composition is useful in the treatment, alleviation or prophylaxis of diseases associated with an elevated cholesterol level.
PE2016002242A 2009-09-03 2010-08-23 PCSK9 vaccine PE15602016A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US23954109P true 2009-09-03 2009-09-03

Publications (1)

Publication Number Publication Date
PE15602016A1 true PE15602016A1 (en) 2017-01-11



Family Applications (3)

Application Number Title Priority Date Filing Date
PE2012000286A PE15442012A1 (en) 2009-09-03 2010-08-23 PCSK9 vaccine
PE2016002242A PE15602016A1 (en) 2009-09-03 2010-08-23 PCSK9 vaccine
PE2016002226A PE15512016A1 (en) 2009-09-03 2010-08-23 PCSK9 vaccine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000286A PE15442012A1 (en) 2009-09-03 2010-08-23 PCSK9 vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016002226A PE15512016A1 (en) 2009-09-03 2010-08-23 PCSK9 vaccine

Country Status (29)

Country Link
US (4) US8889144B2 (en)
EP (3) EP2865752A1 (en)
JP (5) JP2013503623A (en)
KR (2) KR101660577B1 (en)
CN (3) CN104548089B (en)
AR (2) AR078247A1 (en)
AU (1) AU2010290931B2 (en)
BR (1) BR112012004807A2 (en)
CA (2) CA2771770A1 (en)
CO (1) CO6501190A2 (en)
DK (1) DK2473605T3 (en)
ES (1) ES2670576T3 (en)
HK (3) HK1174056A1 (en)
HU (1) HUE037416T2 (en)
IL (2) IL218229A (en)
MX (1) MX2012002639A (en)
MY (1) MY163512A (en)
NO (1) NO2473605T3 (en)
NZ (3) NZ710626A (en)
PE (3) PE15442012A1 (en)
PH (2) PH12016500004A1 (en)
PL (1) PL2473605T3 (en)
PT (1) PT2473605T (en)
RU (2) RU2538162C2 (en)
SG (3) SG178447A1 (en)
SI (1) SI2473605T1 (en)
TR (1) TR201808222T4 (en)
TW (1) TWI400085B (en)
WO (1) WO2011027257A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102203121A (en) 2008-08-29 2011-09-28 口腔健康澳洲私人有限公司 Prevention, treatment and diagnosis of p.gingivalis infection
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PT2376107E (en) 2008-12-09 2014-07-25 Coley Pharm Group Inc Immunostimulatory oligonucleotides
GB201005005D0 (en) * 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
WO2012131504A1 (en) * 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
EP2532359A1 (en) 2011-06-10 2012-12-12 Affiris AG CETP fragments
RS54639B1 (en) * 2011-09-13 2016-08-31 Affiris Ag Pcsk9 vaccine
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2703483A1 (en) * 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
CA2888321A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20150274784A1 (en) * 2012-11-07 2015-10-01 Vacplanta Limted Production of an Immunogen Using a Plant Virus
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
TWI641382B (en) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 A method of virus inactivation in composition comprising factor vii
CN104043120B (en) 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 Hepatitis b vaccine
WO2015123291A1 (en) * 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
MX2016010838A (en) * 2014-02-28 2016-11-17 Affiris Ag Pcsk9 vaccines.
CN104558199B (en) * 2014-09-05 2018-07-06 成都康弘生物科技有限公司 A kind of fusion protein preparation for treating hypercholesterolemia and application thereof
US20180311340A1 (en) 2015-10-19 2018-11-01 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
CN106822881A (en) * 2016-12-09 2017-06-13 四川大学 A kind of hyperlipoproteinemia vaccine for PCSK9
WO2018189705A1 (en) 2017-04-13 2018-10-18 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
JPS6242903B2 (en) 1978-08-04 1987-09-10 Takeda Chemical Industries Ltd
GB2055131B (en) 1978-09-29 1982-12-15 Energy Secretary Of State For Electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
AU548727B2 (en) 1981-03-12 1986-01-02 Gruppo Lepetit S.P.A. Beta-lactam acetic acid derivatives
WO1983001451A1 (en) 1981-10-23 1983-04-28 Molecular Biosystems Inc Oligonucleotide therapeutic agent and methods of making same
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
IL64542D0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPH0455168B2 (en) 1983-12-26 1992-09-02 Eisai Co Ltd
DE3423166A1 (en) 1984-06-22 1986-01-02 Epis Sa Alpha, omega-dicarboxylic acids, process for their preparation and pharmaceutical compositions containing these compounds
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigenic, process for their production and their use
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
JP2999579B2 (en) 1990-07-18 2000-01-17 武田薬品工業株式会社 Dna and its applications
IL98715D0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
JPH06503821A (en) 1990-12-20 1994-04-28
DE4202394A1 (en) 1991-04-04 1992-10-08 Teves Gmbh Alfred Floating-caliper disc brake pad part with a bremsengehaeuse from alloy
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
DE69324487D1 (en) 1992-05-06 1999-05-20 Harvard College Receptor binding region of diphtherietoxius
DE69313134T2 (en) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvants containing vaccine composition
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK0689454T4 (en) 1993-03-23 2005-05-30 Smithkline Beecham Biolog Vaccine preparations containing 3-O-deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (en) 1994-07-15 2004-09-08 Coley Pharmaceutical Group, Inc. Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (en) 1996-10-11 2005-10-16 The Regents Of The University Of California Immuno stimulator polinucleotide conjugates / immunomodulator molecula.
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2283557A1 (en) 1997-03-10 1998-09-17 Heather L. Davis Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant
DE69838294T2 (en) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Process for the preparation of nucleic acid constructs
JP4101888B2 (en) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
IL121165D0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
WO1999040934A1 (en) 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
DE69935507T2 (en) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Method and products for stimulating the immune system by immunotherapeutic oligonucleotides and cytokines
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2188003T3 (en) 1998-09-18 2003-06-16 Pentapharm Ag Urokinase inhibitors.
WO2000021478A1 (en) 1998-09-28 2000-04-20 Hans Balle Aps Lift, preferably for seats on wheelchairs
US6203837B1 (en) 1998-10-06 2001-03-20 Xcafe' Llc Coffee system
IL142395D0 (en) 1998-10-16 2002-03-10 Smithkline Beecham Biolog Adjuvant systems and vaccines
AT314095T (en) 1998-10-21 2006-01-15 Us Health Virusely particles for inducing autoantic bodies
EP1119630B1 (en) 1998-11-05 2006-01-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunisation
WO2000032227A2 (en) 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
CN100398653C (en) 1998-12-23 2008-07-02 益得生物医学公司 Novel streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (en) 1999-02-17 2016-06-02 Csl Limited Immunogenic complexes and related methods
TWI286938B (en) * 1999-03-19 2007-09-21 Smithkline Beecham Biolog Immunogenic compositions comprising polysaccharide conjugate antigens and protein D from haemophilus influenzae, methods of preparing the same and vaccines comprising the same
US6410802B1 (en) 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
EP1165796A2 (en) 1999-04-09 2002-01-02 Department of Health and Human Services Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
JP2002542203A (en) 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム vaccine
NO309798B1 (en) * 1999-04-30 2001-04-02 Targovax As Peptide, as well as pharmaceutical compositions and cancer vaccine comprising peptide
MXPA02003068A (en) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant.
CN1391483A (en) 1999-09-24 2003-01-15 史密丝克莱恩比彻姆生物有限公司 Composition of octoxinol and polyvinyl chloride sorbitanate as accessory and uses in vaccins
IL148844D0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
DE60122300T2 (en) 2000-04-07 2007-08-30 The University Of Leeds Hepatitis b core protein fusion proteins
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
JP5051959B2 (en) 2000-06-20 2012-10-17 アイディー バイオメディカル コーポレイション オブ ケベック Streptococcus antigen
AU6616301A (en) 2000-06-22 2002-01-02 Celltech Pharmaceuticals Ltd Modification of hepatitis b core antigen
WO2002005690A1 (en) 2000-07-15 2002-01-24 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
AP200302752A0 (en) 2000-08-16 2003-06-30 Apovia Inc Immunogenic hbc chimer particles having enhanced stability
AU2002362696B2 (en) 2001-10-05 2008-05-29 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
AU2002339224B2 (en) * 2001-09-14 2008-10-09 Kuros Biosciences Ag Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CN1668637B (en) 2002-07-17 2010-05-26 希托斯生物技术股份公司 Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
AU2003300841B2 (en) 2002-12-10 2008-03-20 Lorantis Ltd. Stabilized immunogenic HBc chimer particles
CA2812817C (en) 2003-03-13 2016-12-20 Glaxosmithkline Biologicals S.A. Method of detoxification of pneumolysin
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JP2008506683A (en) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ, リミテッド Methods and compositions for inducing innate immune responses
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
JP5473336B2 (en) 2006-02-15 2014-04-16 アディウタイド・ファーマスーティカルズ・ゲーエムベーハー Compositions and methods relating to the formulation of oligonucleotides
EP2348106B1 (en) * 2006-05-08 2014-07-02 Adaerata, Limited Partnership Chimeric proteins, cells comprising same, and assays using same
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
EP2142217B1 (en) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted pcsk9
WO2008125623A2 (en) * 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
ES2626662T3 (en) 2007-06-26 2017-07-25 Glaxosmithkline Biologicals S.A. Vaccine comprising capsular polysaccharide conjugates of Streptococcus pneumoniae
TWI441833B (en) * 2007-08-23 2014-06-21 Amgen Inc Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
SG2013014352A (en) * 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
RU2010129538A (en) * 2007-12-20 2012-01-27 Цитос Биотехнологи Аг (Ch) Ngf conjugates and their application
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 antagonists (subtilisin-kexin type proprotein 9)
AR070315A1 (en) * 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 antagonists antibodies 1B20
TWI516501B (en) * 2008-09-12 2016-01-11 Rinat Neuroscience Corp Pcsk9 antagonists
AT507604A1 (en) 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh Treatment of atherosclerosis
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
US10114918B2 (en) 2016-01-27 2018-10-30 Arm Limited Physical placement control for an integrated circuit based on state bounds file

Also Published As

Publication number Publication date
EP3358008A1 (en) 2018-08-08
RU2538162C2 (en) 2015-01-10
PE15442012A1 (en) 2012-12-02
KR20140004263A (en) 2014-01-10
NZ620441A (en) 2015-08-28
AR107020A2 (en) 2018-03-14
TW201113035A (en) 2011-04-16
CN104587462B (en) 2017-09-26
PL2473605T3 (en) 2018-08-31
PH12016500040A1 (en) 2016-12-05
HK1209619A1 (en) 2016-04-08
IL218229A (en) 2017-10-31
CN102612558B (en) 2015-02-11
HUE037416T2 (en) 2018-08-28
US9987341B2 (en) 2018-06-05
CN104587462A (en) 2015-05-06
JP2017039748A (en) 2017-02-23
DK2473605T3 (en) 2018-05-28
BR112012004807A2 (en) 2017-04-11
EP2473605B1 (en) 2018-04-11
CA2846746A1 (en) 2011-03-10
SG178447A1 (en) 2012-03-29
MY163512A (en) 2017-09-15
AU2010290931B2 (en) 2014-02-06
US20110052621A1 (en) 2011-03-03
PT2473605T (en) 2018-05-28
KR20120089451A (en) 2012-08-10
PE15512016A1 (en) 2017-01-18
RU2014143531A3 (en) 2018-06-22
KR101660577B1 (en) 2016-09-27
JP2015131814A (en) 2015-07-23
NO2473605T3 (en) 2018-09-08
EP2473605A2 (en) 2012-07-11
US20180318407A1 (en) 2018-11-08
CO6501190A2 (en) 2012-08-15
IL218229D0 (en) 2012-04-30
AR078247A1 (en) 2011-10-26
US9481875B2 (en) 2016-11-01
AU2010290931A1 (en) 2012-03-29
JP2016106089A (en) 2016-06-16
TWI400085B (en) 2013-07-01
RU2014143531A (en) 2016-05-20
NZ710626A (en) 2017-03-31
WO2011027257A3 (en) 2011-06-30
NZ599059A (en) 2014-05-30
MX2012002639A (en) 2012-03-14
JP2013503623A (en) 2013-02-04
HK1208346A1 (en) 2016-03-04
CN102612558A (en) 2012-07-25
US8889144B2 (en) 2014-11-18
RU2012107657A (en) 2013-10-10
TR201808222T4 (en) 2018-07-23
US20150098957A1 (en) 2015-04-09
US20170100467A1 (en) 2017-04-13
KR101660578B1 (en) 2016-09-27
SI2473605T1 (en) 2018-06-29
HK1174056A1 (en) 2015-10-30
CN104548089A (en) 2015-04-29
JP2018039821A (en) 2018-03-15
CA2771770A1 (en) 2011-03-10
IL254600D0 (en) 2017-11-30
ES2670576T3 (en) 2018-05-31
KR20140007500A (en) 2014-01-17
SG10201401516XA (en) 2014-10-30
SG10201401515YA (en) 2014-08-28
PH12016500004A1 (en) 2016-12-05
WO2011027257A2 (en) 2011-03-10
EP2865752A1 (en) 2015-04-29
CN104548089B (en) 2017-09-26
JP5859150B2 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
JP2009298821A (en) Antigen encoded by alternative reading frame from pathogenic virus
TWI232753B (en) Adjuvant compositions comprising QS-21,3D-MPL and CpG and vaccine compositions comprising the same
EP2278012A3 (en) Avirulent, immunogenic flavivirus chimeras
NZ562929A (en) Immunisation against chlamydia trachomatis
CY1112589T1 (en) Anosogonos composition adjuvanted
RU2364413C2 (en) Immunogenic composition and method for designing vaccine based on h-factor binding sites
EP2351767A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
RU2434638C2 (en) Vaccine of c perfringens alpha toxoid
EP2130921A3 (en) Vaccine for prevention and treatment of hiv-infection
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
GT201300093A (en) antiviral compounds
PE01862014A1 (en) Analogs of glucagon having GIP receptor activity
EA200801221A1 (en) Viral vaccines obtained from cells with low levels of residual cell dna
WO2007062107A3 (en) Immunostimulatory oligoribonucleotides
MXPA05011110A (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
AR027509A1 (en) GCSF conjugates
MX2007013825A (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease.
UY32874A (en) Compounds and compositions as modulators of activity tlr
AR064175A1 (en) Hyaluronic acid gel for intradermal
GT201200020A (en) Composition acting insulin
CY1112749T1 (en) Vaccination STIMULUS / anamnisis AGAINST MALARIA
WO2007095976A3 (en) Adjuvant in the form of a lipid-modified nucleic acid
AR080218A1 (en) Immuno products chorionic membranes
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal